Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology
By A Mystery Man Writer
Description
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Frontiers Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Cancers, Free Full-Text
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. - Abstract - Europe PMC
Frontiers An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer
Cancers, Free Full-Text
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial - ScienceDirect
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Molecularly directed therapy of advanced/metastatic non-small cell lung cancer (CME article)
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial, BMC Cancer
Cancers, Free Full-Text
PDF) Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
from
per adult (price varies by group size)